Abnormal microglial activation in the Cstb-/- mouse, a model for progressive myoclonus epilepsy, EPM1

GLIA

Volumn 63, Issue 3, 2015, Pages 400-411

  Okuneva, Olesya ^a,b,c   Körber, Inken ^a,b,c   Li, Zhilin ^c   Tian, Li ^c   Joensuu, Tarja ^a,b,c   Kopra, Outi ^a,b,c   Lehesjoki, Anna Elina ^a,b,c  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chemokine; Cystatin B; M1 M2; Neuroinflammation; P38 MAPK; Pro inflammatory microglia

Indexed keywords

ARGINASE 1; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYSTATIN B; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; ARG1 PROTEIN, MOUSE; ARGINASE; CSTB PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; ASTROCYTE; BRAIN CELL CULTURE; CELL ACTIVATION; CELL FUNCTION; CELL ISOLATION; CHEMOTAXIS; CHEMOTAXIS ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROGLIA; MICROGLIAL CELL CULTURE; MONONUCLEAR CELL; MOUSE; MYOCLONUS EPILEPSY; NERVE CELL; NONHUMAN; PHENOTYPE; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; 129 MOUSE; ANIMAL; BRAIN; CELL CULTURE; DEFICIENCY; DISEASE MODEL; GENE; GENETICS; GRANULOCYTE; IMMUNOLOGY; IMMUNOMODULATION; MACROPHAGE; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; ARGINASE; ASTROCYTES; BRAIN; CELLS, CULTURED; CYSTATIN B; DISEASE MODELS, ANIMAL; GENES, MHC CLASS II; GRANULOCYTES; MACROPHAGES; MICE, 129 STRAIN; MICROGLIA; NEUROIMMUNOMODULATION; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; T-LYMPHOCYTES; UNVERRICHT-LUNDBORG SYNDROME;

EID: 84920984446     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22760     Document Type: Article

References (60)

1. Akundi RS, Candelario-Jalil E, Hess S, Hüll M, Lieb K, Gebicke-Haerter PJ, Fiebich BL. 2005. Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia 51:199-208.
2. Barna JB, Kew RR. 1995. Inhibition of neutrophil chemotaxis by protease inhibitors. Differential effect of inhibitors of serine and thiol proteases. Inflammation 19:561-574.
3. Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896.
4. Cherry JD, Olschowka JA, O'Banion MK. 2014. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98.
5. Davies ME, Barrett AJ. 1984. Immunolocalization of human cystatins in neutrophils and lymphocytes. Histochemistry 80:373-377.
6. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661-665.
7. Fabene PF, Bramanti P, Constantin G. 2010. The emerging role for chemokines in epilepsy. J Neuroimmunol 224:22-27.
8. Giulian D, Baker TJ. 1986. Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6:2163-2178.
9. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
10. Grandbarbe L, Michelucci A, Heurtaux T, Hemmer K, Morga E, Heuschling P. 2007. Notch signaling modulates the activation of microglial cells. Glia 55:1519-1530.
11. Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG. 2013. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33:9592-9600.
12. Haves-Zburof D, Paperna T, Gour-Lavie A, Mandel I, Glass-Marmor L, Miller A. 2011. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med 15:2421-2429.
13. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J. 2012. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063-3070.
14. Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, Aalto A, Huopaniemi L, Aula N, Michellucci R, Eriksson K, Lehesjoki A-E. 2007. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 15:185-193.
15. Joensuu T, Tegelberg S, Reinmaa E, Segerstråle M, Hakala P, Pehkonen H, Korpi ER, Tyynelä J, Taira T, Hovatta I, Kopra O, Lehesjoki A-E. 2014. Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation. PLoS One 9:e89321.
16. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M. 2009. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat Rec (Hoboken) 292:1902-1913.
17. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. 2011. Physiology of microglia. Physiol Rev 91:461-553.
18. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 2009. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29:13435-13444.
19. Kitamura H, Kamon H, Sawa S, Park SJ, Katunuma N, Ishihara K, Murakami M, Hirano T. 2005. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 23:491-502.
20. Koistinaho M, Koistinaho J. 2002. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 40:175-183.
21. Kopitar-Jerala N, Schweiger A, Myers RM, Turk V, Turk B. 2005. Sensitization of stefin B-deficient thymocytes towards staurosporin-induced apoptosis is independent of cysteine cathepsins. FEBS Lett 579:2149-2155.
22. Koskenkorva P, Khyuppenen J, Niskanen E, Könönen M, Bendel P, Mervaala E, Lehesjoki AE, Kälviäinen R, Vanninen R. 2009. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: voxel-based morphometric study. Neurology 73:606-611.
23. Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. 1974a. Progressive myoclonus epilepsy. A clinical and histopathological study. Acta Neurol Scand 50:307-332.
24. Koskiniemi M, Toivakka E, Donner M. 1974b. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand 50:333-359.
25. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M, Udalova IA. 2011. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12:231-238.
26. Kälviäinen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. 2008. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 49:549-556.
27. Lafrenière RG, Rochefort DL, Chrétien N, Rommens JM, Cochius JI, Kälviäinen R, Nousiainen U, Patry G, Farrell K, Söderfeldt B, Federico A, Hale BR, Cossio OH, Sørensen T, Pouliot MA, Kmiec T, Uldall P, Janszky J, Pranzatelli MR, Andermann F, Andermann E, Rouleau GA. 1997. Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat Genet 15:298-302.
28. Lalioti MD, Scott HS, Buresi C, Rossier C, Bottani A, Morris MA, Malafosse A, Antonarakis SE. 1997. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 386:847-851.
29. Lehtinen MK, Tegelberg S, Schipper H, Su H, Zukor H, Manninen O, Kopra O, Joensuu T, Hakala P, Bonni A, Lehesjoki A-E. 2009. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci 29:5910-5915.
30. Lenarcic B, Krizaj I, Zunec P, Turk V. 1996. Differences in specificity for the interactions of stefins A, B and D with cysteine proteinases. FEBS Lett 395:113-118.
31. Li Z, Ma L, Kulesskaya N, Võikar V, Tian L. 2014. Microglia are polarized to M1 type in high-anxiety inbred mice in response to lipopolysaccharide challenge. Brain Behav Immun 38:237-248.
32. Lieuallen K, Pennacchio LA, Park M, Myers RM, Lennon GG. 2001. Cystatin B-deficient mice have increased expression of apoptosis and glial activation genes. Hum Mol Genet 10:1867-1871.
33. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
34. Luciano-Montalvo C, Ciborowski P, Duan F, Gendelman HE, Melendez LM. 2008. Proteomic analyses associate cystatin B with restricted HIV-1 replication in placental macrophages. Placenta 29:1016-1023.
35. Luciano-Montalvo C, Melendez LM. 2009. Cystatin B associates with signal transducer and activator of transcription 1 in monocyte-derived and placental macrophages. Placenta 30:464-467.
36. MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350.
37. Maher K, Završnik J, Jerič-Kokelj B, Vasiljeva O, Turk B, Kopitar-Jerala N. 2014. Decreased IL-10 expression in stefin B-deficient macrophages is regulated by the MAP kinase and STAT-3 signaling pathways. FEBS Lett 588:720-726.
38. Manninen O, Koskenkorva P, Lehtimäki KK, Hyppönen J, Könönen M, Laitinen T, Kalimo H, Kopra O, Kälviäinen R, Gröhn O, Lehesjoki A-E, Vanninen R. 2013. White matter degeneration with Unverricht-Lundborg progressive myoclonus epilepsy: a translational diffusion-tensor imaging study in patients and cystatin B-deficient mice. Radiology 269:232-239.
39. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, Brochet B, Canron MH, Franconi J-M, Boiziau C, Petry KG. 2011. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 17:2-15.
40. Munder M. 2009. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 158:638-651.
41. Nomura H, Furuta A, Tanaka Y, Iwaki T. 2005. Forced retraction of spinal root injury enhances activation of p38 MAPK cascade in infiltrating macrophages. Neuropathology 25:37-47.
42. Norio R, Koskiniemi M. 1979. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 15:382-98.
43. Okamoto OK, Janjoppi L, Bonone FM, Pansani AP, da Silva AV, Scorza FA, Cavalheiro EA. 2010. Whole transcriptome analysis of the hippocampus: toward a molecular portrait of epileptogenesis. BMC Genomics 11:230.
44. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. 1998. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet 20:251-258.
45. Pennacchio LA, Lehesjoki A-E, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington JA, Norio R, de la Chapelle A, Cox DR, Myers RM. 1996. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271:1731-1734.
46. Pennacchio LA, Myers RM. 1996. Isolation and characterization of the mouse cystatin B gene. Genome Res 6:1103-1109.
47. Pino PA, Cardona AE. 2011. Isolation of brain and spinal cord mononuclear cells using percoll gradients. J Vis Exp.
48. Riese RJ, Chapman HA. 2000. Cathepsins and compartmentalization in antigen presentation. Curr Opin Immunol 12:107-113.
49. Rinne A, Jarvinen M, Dorn A, Alavaikko M, Jokinen K, Hopsu-Havu VK. 1986. Low-molecular cysteine protease inhibitors in the human palatal tonsil. Anat Anz 161:215-230.
50. Staun-Ram E, Miller A. 2011. Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-beta and role played in cell migration. J Neuroimmunol 232:200-206.
51. Tegelberg S, Kopra O, Joensuu T, Cooper JD, Lehesjoki AE. 2012. Early microglial activation precedes neuronal loss in the brain of the Cstb-/- mouse model of progressive myoclonus epilepsy, EPM1. J Neuropathol Exp Neurol 71:40-53.
52. Turk V, Bode W. 1991. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285:213-219.
53. Turk V, Stoka V, Turk D. 2008. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 13:5406-5420.
54. Wang G, Zhang J, Hu X, Zhang L, Mao L, Jiang X, Liou AK, Leak RK, Gao Y, Chen J. 2013. Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab 33:1864-1874.
55. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang Y-M, Han H. 2010. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70:4840-4849.
56. Verdot L, Lalmanach G, Vercruysse V, Hartmann S, Lucius R, Hoebeke J, Gauthier F, Vray B. 1996. Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. J Biol Chem 271:28077-28081.
57. Virtaneva K, D'Amato E, Miao J, Koskiniemi M, Norio R, Avanzini G, Franceschetti S, Michelucci R, Tassinari CA, Omer S, Pennacchio LA, Myers RM, Dieguez-Lucena JL, Krahe R, de la Chapelle A, Lehesjoki A-E. 1997. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 15:393-6.
58. Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K. 2011. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 11:45-59.
59. Zavasnik-Bergant T. 2008. Cystatin protease inhibitors and immune functions. Front Biosci 13:4625-37.
60. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B. 2009. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57:1458-1467.